Skip Navigation

Cardiovascular Research 1995 30(4):593-601; doi:10.1016/S0008-6363(95)00093-3
© 1995 by European Society of Cardiology
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maulik, N.
Right arrow Articles by Das, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maulik, N.
Right arrow Articles by Das, D. K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1995, European Society of Cardiology

Nitric oxide signaling in ischemic heart

Nilanjana Maulika, Daniel T. Engelmana, Masazumi Watanabea, Richard M. Engelmanb, Gautam Maulika, Gerald A. Cordisa and Dipak K. Das*

aCardiovascular Division, Department of Surgery, University of Connecticut School of Medicine, Farmington, CT 06030-1110, USA
bBaystate Medical Center, Springfield, MA 01199, USA

* Corresponding author. Tel (+203) 679-3867; Fax (+203) 679-2451.

Objective: Several recent studies have implicated a role of endogenous nitric oxide (NO) in the pathophysiology of myocardial ischemic/reperfusion injury. However, the mechanism by which NO exerts its beneficial/detrimental effects remains unknown. This study examined the intracellular signaling of NO by studying the role of the NO-cGMP signaling pathway on the phospho-diesteratic breakdown and turnover of phosphoinositides during myocardial ischemia and reperfusion. Methods: Isolated working rat hearts were made ischemic for 30 min followed by 30 min of reperfusion. A separate group of hearts were pre-perfused with 3 mM L-arginine for 10 min prior to ischemia. The release of NO was monitored using an on-line amperometric sensor. The aortic flow and developed pressure were examined to determine the effects of L-arginine on ischemic/reperfusion injury. For signal transduction experiments, sarcolemmal membranes were radiolabeled by perfusing the isolated hearts with [3H] myoinositol and [14C] arachidonic acid. Hearts were then perfused for 10 min in the presence or absence of L-arginine via the Langendorff mode. Ischemia was induced for 30 min followed by 30 min of reperfusion. Experiments were terminated before L-arginine and after L-arginine treatment, after ischemia, and during reperfusion. Biopsies were processed to determine the isotopic incorporation into various phosphoinositols as well as phosphatidic acid and diacylglycerol. cGMP was assayed by radioimmunoassay and SOD content was determined by enzymatic analysis. Results: The release of NO was diminished following ischemia and reperfusion and was augmented by L-arginine. L-Arginine reduced ischemic/reperfusion injury as evidenced by the enhanced myocardial functional recovery. cGMP, which remained unaffected by ischemia and reperfusion, was stimulated significantly after L-arginine treatment. The cGMP level persisted up to 10 min of reperfusion and then dropped slightly. Reperfusion of ischemic myocardium resulted in significant accumulation of radiolabeled inositol phosphate, inositol bisphosphate, and inositol triphosphate. Isotopic incorporation of [3H]inositol into phosphatidylinositol, phosphatidylinositol-4-phosphate, and phosphatidylinositol-4,5-bisphosphate was increased significantly during reperfusion. Reperfusion of the ischemic heart prelabeled with [14C]-arachidonic acid resulted in modest increases in [14C]diacylglycerol and [14C]phosphatidic acid. Pretreatment of the heart with L-arginine significantly reversed this enhanced phosphodiesteratic breakdown during ischemia and early reperfusion. However, at the end of the reperfusion the inhibitory effect of L-arginine on the phosphodiesterases seems to be reduced. In L-arginine-treated hearts, SOD activity was progressively decreased with the duration of reperfusion time. Conclusions: The results suggest for the first time that NO plays a significant role in transmembrane signaling in the ischemic myocardium. The signaling seems to be transmitted via cGMP and opposes the effects of phosphodiesterases by inhibiting the ischemia/reperfusion-induced phosphodiesteratic breakdown. This signaling effect appears to be reduced as reperfusion progresses. These results, when viewed in the light of free radical chemistry of NO, suggest that such on- and off-signaling of NO may be linked to its interaction with the superoxide radical generated during the reperfusion of ischemic myocardium.

KEYWORDS Nitric oxide; Signal transduction; Phosphoinositides; cGMP; Myocardial ischemia; Reperfusion; Free radicals


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
F. Padilla, D. Garcia-Dorado, L. Agullo, J. A Barrabes, J. Inserte, N. Escalona, M. Meyer, M. Mirabet, P. Pina, and J. Soler-Soler
Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs
Cardiovasc Res, August 15, 2001; 51(3): 592 - 600.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L.-M. Hung, J.-K. Chen, S.-S. Huang, R.-S. Lee, and M.-J. Su
Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes
Cardiovasc Res, August 18, 2000; 47(3): 549 - 555.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. Greenberg, G. Chemin, I. Shapira, J. George, Y. Wollman, S. Laniado, and G. Keren
Captopril and L-Arginine Have a Synergistic Cardioprotective Effect in Ischemic-Reperfusion Injury in the Isolated Rat Heart
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 281 - 290.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
S. B Felix, V. Stangl, T. M Frank, C. Harms, T. Berndt, R. Kastner, and G. Baumann
Release of a stable cardiodepressant mediator after myocardial ischaemia during reperfusion
Cardiovasc Res, July 1, 1997; 35(1): 68 - 79.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.